Tag Archives: SERVE-HF

The 2016 guidelines include for the first time the new drug sacubitril/valsartan (previously known as LCZ696). This is the first drug in the class of angiotensin receptor neprilysin inhibitors (ARNIs) and was shown in the PARADIGM-HF trial to be superior to the angiotensin-converting enzyme (ACE) inhibitor enalapril for reducing the risk of death and hospitalisation in patients with heart failure with reduced ejection fraction (HFREF) who met strict inclusion and exclusion criteria. Professor Piotr Ponikowski (Chairperson of the ESC Guidelines Task Force), said: “The issue of how to include LCZ696 in the treatment algorithm generated a lot

(more…)

An overlooked form of SDB Professor Martin Cowie Another form of sleep apnoea – central sleep apnoea with Cheyne Stokes respiration (CSA-CSR) – has received less in-depth investigation than OSA. Nonetheless, it carries significant importance, particularly in heart failure patients. Moderate-to-severe forms have been reported to occur in up to 50% of chronic heart failure patients.4-7 Unlike OSA patients, whose loud night-time snores are punctuated with dramatic apnoeic episodes, CSA-CSR patients exhibit a different style of breathing. In this patient group, night-time breathing follows a waxing and waning pattern in which successive breat